KEAP1 and head and neck cancer: In our case, only 2 of 13 patients (16%) in the tumor without HN-CSC group had lung metastasis but had a better therapeutic response, suggesting that Keap1/Nrf2 mutations in HN-CSCs may be partially responsible for head and neck cancer lung metastasis and the least therapeutic outcome.